Business
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel,a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regul
About this update from Bio-techne Corp
[{"type":"list","items":[{"val":[{"type":"text","content":"Fully defined, synthetic ECM designed to improve reproducibility and reduce lot-to-lot variability","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Supports standardization of scalable 3D stem cell and organoid workflows","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Synthetic alternative to traditional matrices, enabling consistent performance while aligning with regulatory and translational initiatives","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"MINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices.","length":641,"tagName":"p"},{"type":"text","content":"Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture.","length":546,"tagName":"p"},{"type":"text","content":"Cultrex Synthetic Hydrogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic Hydrogel launch represents an impo...